- New Zealand
- /
- Pharma
- /
- NZSE:BLT
BLIS Technologies Full Year 2025 Earnings: EPS: NZ$0.001 (vs NZ$0.001 in FY 2024)
BLIS Technologies (NZSE:BLT) Full Year 2025 Results
Key Financial Results
- Revenue: NZ$13.1m (up 13% from FY 2024).
- Net income: NZ$838.0k (up 30% from FY 2024).
- Profit margin: 6.4% (up from 5.6% in FY 2024). The increase in margin was driven by higher revenue.
- EPS: NZ$0.001 (in line with FY 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BLIS Technologies shares are up 14% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 2 warning signs for BLIS Technologies (1 makes us a bit uncomfortable) you should be aware of.
If you're looking to trade BLIS Technologies, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if BLIS Technologies might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NZSE:BLT
BLIS Technologies
Develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity.
Flawless balance sheet with solid track record.
Market Insights
Community Narratives


